Mosunetuzumab (Lunsumio; RG7828; CAS 1905393-16-1): NIOSH HD Category 1 SIXTY-SEVENTH Mechanism Class [FIRST CD20 (MS4A1; 4-TM; No Ligand; B-Cell Pre-B→Memory; Absent Plasma Cells) × CD3ε BISPECIFIC T-CELL ENGAGER EVER FDA APPROVED (BLA 761263; Sep 22, 2022; CrossMAb KiH T366W/T366S-L368A-Y407V + Common LC + IgG1 LALA-PG Fc Silencing Leu234Ala/Leu235Ala/Pro329Gly; Genentech/Roche)] + FIRST FIXED-DURATION BISPECIFIC T-CELL ENGAGER FOR ANY LYMPHOMA (≤17 Cycles; Discontinuation on Sustained CR; GO29781 ORR 80.0% CR 59.9%); Genentech South San Francisco CA Cority ÷10; Roche Biologics Vacaville CA VelocityEHS ÷10; Stanford Cancer Center Stanford CA EHS Insight ÷10; Glyphward Threshold 22; 640th Adversarial Attack; 145th Long-Form Blog

Mosunetuzumab (Lunsumio®; RG7828; BTCT4465A; mosunetuzumab-axgb; CAS 1905393-16-1; MW ∼148,000 Da IgG1 kappa asymmetric bispecific antibody; anti-CD20 [MS4A1] × anti-CD3ε; CrossMAb technology [Roche/Genentech]; NIOSH HD Category 1; BLA 761263; MECHANISM: SIXTY-SEVENTH MECHANISM CLASS in the 640-ATTACK GLYPHWARD ADVERSARIAL PORTFOLIO — FIRST CD20 (MEMBRANE-SPANNING 4A FAMILY MEMBER 1; MS4A1; gene 11q12.2; ~37 kDa; 4-pass transmembrane; no known extracellular ligand; no internalization upon antibody binding; expressed pre-B through mature memory B cells; ABSENT on plasma cells; ~98% follicular lymphoma cells) × CD3ε BISPECIFIC T-CELL ENGAGER EVER FDA APPROVED IN ANY INDICATION, WORLDWIDE (BLA 761263 September 22, 2022); CrossMAb TECHNOLOGY: knobs-into-holes CH3 heterodimerization (T366W knob + T366S/L368A/Y407V hole on anti-CD3ε HC) + common light chain (CLC; single shared κ LC pairs with both anti-CD20 HC and anti-CD3ε HC) + IgG1 LALA-PG Fc silencing (Leu234Ala/Leu235Ala/Pro329Gly → eliminates FcγRI/IIa/IIIa + C1q binding; FcRn retained → t½ ∼2–3 weeks → Q3W IV dosing); FIRST FIXED-DURATION BISPECIFIC T-CELL ENGAGER FOR ANY LYMPHOMA: ≤17 cycles then discontinuation (distinct from blinatumomab continuous indefinite 28-day IV cycles [class 57] and teclistamab indefinite QW/Q2W SC [class 66]); step-up dosing 1 mg→2 mg→60 mg Q3W IV; GO29781 Phase 2 (NCT02500407): n=90 R/R FL Grade 1–3A ≥2 prior lines: ORR 80.0%; CR 59.9%; DOR median 22.8 months; PFS median 17.9 months; CRS 39.9% (Grade 1–2; Grade 3+ 1.1%); Genentech Inc. South San Francisco CA (BLA 761263 US holder); H360; OSHA No PEL; ACGIH No TLV; NIOSH No REL; 640th adversarial attack; 145th long-form blog).

SIXTY-SEVENTH MECHANISM CLASS: CD20 as a B-Cell Surface Antigen and the Rationale for CD20×CD3 Bispecific T-Cell Engagement

The sixty-sixth mechanism class in the Glyphward adversarial portfolio — teclistamab (Tecvayli; JNJ-64007957; first BCMA×CD3 bispecific T-cell engager ever; DuoBody IgG4 Fab-arm exchange; attack #639; blog #144; blog #144) — established the BCMA×CD3 bispecific modality in multiple myeloma using a full-length IgG4 antibody and in vitro Fab-arm exchange (DuoBody; Genmab). The SIXTY-SEVENTH class — mosunetuzumab and the CrossMAb CD20×CD3 bispecific platform — extends the bispecific T-cell engager field into B-cell lymphoma using a full-length IgG1 antibody with KiH heterodimerization and a critical Fc-silencing innovation that distinguishes it from all prior anti-CD20 antibody approvals.

CD20 (MEMBRANE-SPANNING 4A FAMILY MEMBER 1; MS4A1; gene 11q12.2; 297 amino acids; MW ∼37 kDa; no signal peptide; 4-pass transmembrane protein; two extracellular loops [loop 1: residues 33–51; loop 2 [large extracellular loop; LEL]: residues 141–203]) was discovered in 1988 by Nadler et al. as the B1 antigen on human B cells. Several properties make CD20 uniquely suited as a lymphoma therapeutic target: (1) HIGH B-CELL SURFACE DENSITY: CD20 is expressed at ~100,000–300,000 copies per B cell surface, enabling high-avidity antibody binding; (2) NO INTERNALIZATION: unlike CD19 and CD22, CD20 does not internalize upon antibody binding under physiological conditions (CD20 lacks an endocytic sorting motif; it forms large-order oligomers anchored in membrane lipid microdomains [for type I anti-CD20 antibodies] or outside rafts [for type II; obinutuzumab]; non-internalization enables prolonged surface engagement by bound antibodies); (3) NO KNOWN SOLUBLE ISOFORM: unlike BCMA (where soluble sBCMA shed by ADAM10/17 acts as a decoy for teclistamab), CD20 has no known proteolytic sheddase; no soluble CD20 decoy in circulation; (4) B-CELL LINEAGE RESTRICTION: CD20 is expressed exclusively from the pre-B cell through mature memory B cell stages; absent from plasma cells (hence anti-CD20 therapy does NOT deplete immunoglobulin-secreting plasma cells directly — the major difference from BCMA targeting); absent from hematopoietic stem cells (HSC); absent from T cells, NK cells, granulocytes, monocytes, and essentially all non-hematopoietic tissues (rare scattered CD20+ T cells reported but not clinically significant).

FOLLICULAR LYMPHOMA CD20 EXPRESSION: CD20 is expressed on >98% of follicular lymphoma (FL) cells by immunohistochemistry (IHC) or flow cytometry; FL cells are malignant germinal center B lymphocytes (CD20+, CD10+, BCL6+, BCL2+, CD5−, CD23 variable, IgM or IgG/IgA surface immunoglobulin); the t(14;18)(q32;q21) translocation overexpresses BCL2 antiapoptotic protein under IgH enhancer control; FL cells reside in lymph nodes (>90%), bone marrow (~70% of patients), spleen; THE CASE FOR CD20×CD3 BISPECIFIC vs ANTI-CD20 MONOCLONAL: prior anti-CD20 monoclonals (rituximab type I; obinutuzumab type II; class 59 in Glyphward portfolio) kill FL cells primarily via ADCC (NK-cell FcγRIIIa) and CDC (complement C1q); in R/R FL after multiple prior anti-CD20-containing regimens, resistance mechanisms include: (a) CD20 ANTIGEN LOSS/REDUCTION (anti-CD20 mAb-driven CD20 downregulation via lipid raft disruption [type I] or CD20-epitope shielding); (b) NK CELL DEPLETION (prior anti-CD20-based chemotherapy depletes NK cells, reducing ADCC efficacy); (c) COMPLEMENT CONSUMPTION (exhausted complement factors in heavily pre-treated patients); mosunetuzumab BYPASSES these resistance mechanisms: the anti-CD3ε arm recruits HOST CD4+ AND CD8+ T CELLS (not NK cells) regardless of NK depletion; T-cell cytotoxicity is MHC-class-I-independent (does not require tumor cell MHC-I expression, which can be lost in lymphoma); T-cell killing is not complement-dependent; even if CD20 expression is reduced (but not absent), residual CD20 on the FL cell surface is sufficient to anchor mosunetuzumab and bring T cells to proximity.

COMPARISON WITH PRIOR CD20-TARGETING THERAPIES IN THE GLYPHWARD PORTFOLIO: rituximab (Rituxan; chimeric murine/human IgG1 anti-CD20; first therapeutic monoclonal antibody approved in oncology [FDA 1997]; BLA 103705; Genentech/Biogen Idec; IgG1 kappa; binds CD20 LEL loop 2 outer face [type I epitope; inside lipid rafts]; CDC [C1q → MAC] + ADCC [FcγRIIIa] + direct apoptosis [homotypic adhesion; caspase-independent]; no class number in current portfolio; foundational anti-CD20 mechanism); obinutuzumab (Gazyva; GA101; CAS 949142-67-0; NIOSH HD Category 1; first type II anti-CD20 antibody; sixty-first mechanism class; attack #632; GlycoMab IgG1 glycoengineered [bisecting GlcNAc via GnTIII overexpression in CHO → afucosylation → enhanced FcγRIIIa → enhanced ADCC]; type II CD20 antibody [LEL loop 2 inner face; outside lipid rafts → reduced CDC + enhanced homotypic B-cell adhesion + direct lysosomal apoptosis]; BLA 125486 2013); MOSUNETUZUMAB adds the CD3ε arm to the CD20 targeting framework: full-length IgG1 bispecific (CrossMAb) → T-cell cytotoxic mechanism that is COMPLEMENTARY to but DISTINCT from NK-mediated ADCC and complement-mediated CDC; crucially, mosunetuzumab's LALA-PG mutations eliminate its own IgG1-mediated ADCC and CDC, making T-cell killing the PRIMARY and near-exclusive mechanism — a mechanistic distinction from both rituximab and obinutuzumab in which Fc effector functions are a major component of anti-tumor activity.

None of this CD20 biology — MS4A1 expression pattern, type I vs type II CD20 epitope, no internalization/no soluble decoy, 4-pass TM structure, B-cell lineage restriction, FL 98% expression, CrossMAb bispecific T-cell engager mechanism, LALA-PG Fc silencing — is present in Cority, VelocityEHS, or EHS Insight at CAS 1905393-16-1.

CrossMAb Technology: Knobs-into-Holes, Common Light Chain, and IgG1 LALA-PG Fc Silencing

THE BISPECIFIC ANTIBODY MANUFACTURING CHALLENGE: generating a correctly paired full-length IgG bispecific antibody from two distinct antigen specificities requires solving two independent pairing problems that do not arise in conventional monospecific IgG production.

HEAVY CHAIN MISPAIRING PROBLEM: IgG heavy chains homodimerize via the CH3-CH3 interface (14 inter-chain contacts; KD ~10⁻⁶ M for IgG1 CH3-CH3; very stable symmetric homodimerization); co-expressing two different heavy chains (HCA: anti-CD20; HCB: anti-CD3ε) in a single CHO cell follows binomial statistics: ~25% HCA-HCA homodimer + ~50% HCA-HCB heterodimer (desired bispecific) + ~25% HCB-HCB homodimer; purification of the desired 50% heterodimer from the 50% contaminating homodimers requires specific engineering. KNOBS-INTO-HOLES SOLUTION (Ridgway JB et al. Protein Engineering 1996; Carter P et al. J Immunol Methods 2001): inspired by protein-protein interface redesign principles, Genentech researchers introduced steric mutations at the CH3-CH3 interface: T366W KNOB MUTATION on HCA (anti-CD20 heavy chain): Thr366 at the CH3-CH3 hydrophobic interface is replaced by Trp (tryptophan; bulky bicyclic indole side chain; MW increase +65 Da at this position; protrudes like a “knob” into the interface cavity); T366S + L368A + Y407V HOLE MUTATIONS on HCB (anti-CD3ε heavy chain): three mutations (Thr366→Ser; Leu368→Ala; Tyr407→Val) reduce side chain volumes at the CH3 interface to create a complementary cavity accommodating the T366W knob; THERMODYNAMIC OUTCOME: the Trp-knob of HCA has steric clash with the unmodified His361/Tyr349/Thr394 of an identical HCA (homodimerization penalized by steric strain); the Trp-knob fits snugly into the Ser366/Ala368/Val407 cavity of HCB (heterodimer stabilized); HCB-HCB homodimerization: two Ser/Ala/Val-mutated chains have poor CH3 interface fit (cavity-cavity mismatch); NET RESULT: KiH selectively drives heavy chain heterodimerization to ~95–99% of the desired anti-CD20/anti-CD3ε heavy chain pairs at protein expression; this dramatically reduces homodimer contamination compared to unstabilized co-expression (50% → ~2-5% homodimer).

LIGHT CHAIN MISPAIRING PROBLEM: each IgG heavy chain (VH-CH1-hinge-Fc) pairs with a light chain (VL-CL) via the CH1:CL interface; anti-CD20 VH pairs with anti-CD20 VL/CL (LCA; designated for anti-CD20 Fab); anti-CD3ε VH pairs with anti-CD3ε VL/CL (LCB; designated for anti-CD3ε Fab); if KiH-CHO cells also express BOTH LCA and LCB, four heavy chain-light chain pairs can form (HCA-LCA: correct; HCA-LCB: mismatch; HCB-LCA: mismatch; HCB-LCB: correct); even with KiH enforcing correct heavy chain pairing, light chain mispairing produces 4 species from the 2 possible light chain associations; COMMON LIGHT CHAIN SOLUTION (used for mosunetuzumab): Roche/Genentech selects a SINGLE shared light chain variable domain (VL-CL) that can productively pair with BOTH the anti-CD20 VH (forming a functional anti-CD20 Fab) and the anti-CD3ε VH (forming a functional anti-CD3ε Fab); the common VL is identified by screening large antibody libraries (phage display; yeast surface display; MATCH/GEMINI approaches) for VL sequences compatible with both VH partners while maintaining acceptable KD for CD20 (10–100 nM range) and CD3ε (low nM range); with ONE common LC, the CHO expression system uses only three plasmids (HCA-KiH-knob + HCB-KiH-hole + common LC); the 10-species combination problem is reduced to ~2 species (desired heterobispecific HCA-HCB[common LC] + minimal homodimers [KiH-suppressed]); CROSSMAB ADDITIONAL CH1:CL DOMAIN EXCHANGE: Roche's CrossMAb (Schaefer W et al. PNAS 2011; Klein C et al. mAbs 2012) adds a DOMAIN EXCHANGE strategy to further resolve any residual light chain mispairing: in the anti-CD3ε Fab arm of mosunetuzumab, the CH1 and CL domains are SWAPPED: the anti-CD3ε heavy chain carries CL (instead of CH1) at its Fab constant region; the common light chain carries CH1 (instead of CL) for its pairing with the anti-CD3ε HC; this CrossLight exchange creates a charged asymmetry (CH1:CH1 vs CL:CL vs CH1:CL) that CHARGE-DISFAVORS mis-pairing of the common LC with the knob HC when it should be pairing with the hole HC; the CH1:CL exchange does not affect CD3ε binding (the VL-VH interaction that defines specificity is preserved); it is a purely combinatorial pairing selector.

IgG1 BACKBONE WITH LALA-PG FC SILENCING: the choice of IgG1 Fc (vs IgG4 in teclistamab) for mosunetuzumab was made for SERUM HALF-LIFE reasons: IgG1 Fc has higher pH-6 FcRn affinity than IgG4 → better recycling in endosomes → longer serum t½ (~21–28 days for IgG1 vs ~17 days for IgG4); this longer half-life enables less frequent IV dosing (Q3W vs Q1W or Q2W); the CHALLENGE with IgG1 Fc: IgG1 Fc has high affinity for FcγRIII (CD16a; NK cells; mediates ADCC; KD ~40 nM) and activates complement (C1q; mediates CDC); for a CD3-engaging bispecific, an active IgG1 Fc would cause: (1) FcγR-mediated NK cell / macrophage activation independent of CD3 cross-linking → excess cytokine release → increased CRS risk beyond T-cell mechanism; (2) CDC of bystander B cells bearing CD20 (even without T-cell involvement); LALA-PG SOLUTION (Schlothauer T et al. Protein Engineering 2016; Sazinsky SL et al. PNAS 2008): three point mutations in the IgG1 Fc CH2 domain eliminate Fc effector functions: Leu234Ala (L234A; LALA position 1): Leu234 in the CH2 lower hinge adapts the hinge conformation for FcγR binding; Leu234→Ala eliminates the hydrophobic contact that orients the CH2 for FcγRI/IIa/IIIa engagement; Leu235Ala (L235A; LALA position 2): Leu235 in the adjacent hinge position provides a hydrophobic core contact for FcγR; Leu235→Ala cooperates with L234A to reduce FcγRI binding >1000-fold, FcγRIIa >1000-fold, FcγRIIIa >1000-fold; LALA (L234A/L235A) was the original Fc-silencing mutation pair used for many early engineered antibodies; Pro329Gly (P329G; Sondermann 2013): Pro329 in CH2 contributes to the proline-corner structure that enables C1q complement binding; Pro329→Gly disrupts this structural element → C1q binding eliminated → CDC ablated; LALA alone does not fully suppress C1q; LALA-PG (all three) achieves: FcγRI binding <1% vs IgG1 WT; FcγRIIa binding <1%; FcγRIIIa binding <1%; C1q binding <1% (no CDC); ADCP (antibody-dependent cellular phagocytosis; FcγRII-mediated) also eliminated; FcRn binding PRESERVED (FcRn binds at His310 / His435 / Asn434 of CH2-CH3 junction; this site is structurally remote from the lower hinge/CH2 Leu234/Leu235/Pro329 positions affected by LALA-PG) → t½ ∼2–3 weeks maintained; NET RESULT of LALA-PG: mosunetuzumab's IgG1 Fc is completely Fc-effector-function silent (no ADCC; no ADCP; no CDC) while retaining full FcRn recycling for Q3W dosing; T-CELL KILLING IS THE SOLE ANTI-TUMOR MECHANISM of mosunetuzumab — the Fc is purely a pharmacokinetic scaffold; this is mechanistically cleaner than prior anti-CD20 antibodies (rituximab/obinutuzumab) where Fc-mediated ADCC and CDC co-contribute to tumor killing; STEP-UP DOSING (CRS MITIGATION): despite LALA-PG eliminating Fc-mediated cytokine sources, CD3ε cross-linking by the bispecific still activates T cells → T-cell-derived CRS (TNF-α, IL-6, IL-2, IFN-γ); the 1 mg→2 mg→60 mg step-up progressively activates T-cell pools (priming at subtherapeutic dose) before full 60 mg exposure; CRS in GO29781 was any grade 39.9% (Grade 1–2; Grade 3+ 1.1%) — substantially LOWER than blinatumomab (50–60% any CRS; Grade 3–4 CRS ~2%) at therapeutic doses — suggesting the LALA-PG Fc silencing + fixed dose step-up is effective at limiting CRS severity.

Follicular Lymphoma: Pathobiology, t(14;18) BCL2, Treatment Landscape, and the ≥2 Prior Lines Unmet Need

Follicular lymphoma is the most common indolent NHL (~15,000 US cases/year; 5-year overall survival ~85–90% but incurable with current therapies for most patients); the disease is characterized by recurrent relapses requiring multiple lines of therapy over the patient's lifetime. FOLLICULAR LYMPHOMA PATHOBIOLOGY: FL cells are malignant germinal center B lymphocytes arising from the GC reaction (characterized by BCL6+ transcriptional program activating AID [activation-induced cytidine deaminase] for somatic hypermutation and class switch recombination); BCL2 OVEREXPRESSION from t(14;18)(q32;q21): the hallmark translocation places the BCL2 gene under IgH enhancer control; BCL2 is the founding anti-apoptotic BH3-family member (heterodimerizes with pro-apoptotic partners BIM/PUMA/NOXA; sequesters them; prevents BAX/BAK activation; prevents MOMP; blocks cytochrome c → apoptosome → caspase-9 → caspase-3 cascade); in normal GC B cells, BCL2 is transiently suppressed during the GC reaction (allowing negative selection of low-affinity B cells) but t(14;18) restores constitutive BCL2 expression; this BCL2 survival advantage allows GC B cells with t(14;18) to survive and accumulate additional oncogenic mutations; SECONDARY MUTATIONS DRIVING FL PROGRESSION: MLL2/KMT2D (~89% FL; H3K4 methyltransferase; epigenetic activator; bivalent chromatin regulation); CREBBP (~65% FL; CREB-binding protein; histone acetyltransferase; regulates BCL6/IRF4 balance in GC); EP300 (~13%; p300 HAT; paralog of CREBBP); EZH2 (~25% FL; PRC2 H3K27me3 methyltransferase; Y641 gain-of-function mutations [Y641F/H/N/C/S] create neomorphic H3K27me3 hypermethylation → GC retention signal; tazemetostat [class 48] targets EZH2 Y641-mutant FL and wild-type FL via PRC2 complex dependency); TNFRSF14/HVEM (~40% FL; deletion 1p36; type-II transmembrane TNFR family member; HVEM binds BTLA and CD160 coinhibitory receptors on T cells → normally suppresses anti-tumor T-cell responses; loss of HVEM → disrupted T-cell checkpoint suppression → paradoxically potentially MORE T-cell activity in HVEM-deleted FL); FL TRANSFORMATION: ~30% of FL patients transform to diffuse large B-cell lymphoma (DLBCL) over 10 years; transformation is associated with TP53 mutation, MYC rearrangement (double-hit), and additional cytogenetic events; median survival post-transformation ~1–2 years historically (improved with CAR-T).

FRONT-LINE FL THERAPY: stage I–II: involved-site radiation therapy (ISRT; 24 Gy in 12 fractions; curative intent in ~50% at 10 years; National Cancer Institute collaborative trials); stage III–IV LOW tumor burden (GELF criteria: no B-symptoms; no node >7 cm; no >3 sites >3 cm; LDH ≤ULN; no cytopenia; no effusion): WATCHFUL WAITING (RESORT; E4402: rituximab re-treatment equally effective as rituximab maintenance for low-burden FL; 3-year FFS not different; quality-of-life superior for W&W); stage III–IV HIGH tumor burden: B-CELL INDUCTION CHEMOTHERAPY + ANTI-CD20 MONOCLONAL (R-CHOP: rituximab+cyclophosphamide+doxorubicin+vincristine+prednisone; PRIMA OS HR 0.99 non-significant; PFS HR 0.62 with 2-year rituximab maintenance; BR: bendamustine+rituximab [BRIGHT study FL subgroup 5-yr PFS 65%]; G-CHOP/G-benda: obinutuzumab+CHOP or +benda [GALLIUM PFS HR 0.66 for obinutuzumab-based vs rituximab-based; OS no significant difference; obinutuzumab maintenance 2 years after induction]); SECOND-LINE FL THERAPY (first relapse): re-challenge with anti-CD20+chemoimmunotherapy (if CR duration >2 years: retreatment with same [R-CHOP repeat; BR repeat]); or switch to alternate anti-CD20+chemotherapy backbone; lenalidomide+rituximab (AUGMENT PFS HR 0.46 for R/R FL; median PFS 39.4 vs 14.1 months); THIRD-LINE AND BEYOND (≥2 PRIOR LINES; BLA 761263 INDICATION): PI3K INHIBITORS (copanlisib IV Bayer NDA/BLA; idelalisib PI3Kδ; duvelisib PI3Kδ/γ); EZH2 INHIBITOR tazemetostat (Tazverik; Epizyme/Ipsen; NDA 213400; [class 48 in portfolio]; EZH2 Y641-mutant FL ORR 69%; WT-EZH2 FL ORR 35%); AND NOW mosunetuzumab (BLA 761263; first CD20×CD3 bispecific; fixed duration; ORR 80%).

THE ≥2 PRIOR LINES UNMET NEED: patients in GO29781 had received a median 3 prior lines (range 2–10); all had received prior anti-CD20 monoclonal antibody therapy (100%); 81% had received rituximab-based; 27% obinutuzumab-based; by this line of therapy, anti-CD20 monoclonal antibody Fc-mediated efficacy (ADCC and CDC) is likely diminished due to: anti-CD20 resistance, NK cell depletion from prior chemotherapy, complement exhaustion; mosunetuzumab BYPASSES Fc-mediated resistance via T-cell killing (CD3ε arm + LALA-PG silent Fc) — a conceptually distinct anti-tumor mechanism even for anti-CD20-refractory FL.

GO29781 Phase 2 Trial: First Fixed-Duration Bispecific T-Cell Engager for Follicular Lymphoma (ORR 80%, CR 59.9%)

GO29781 (NCT02500407) was the pivotal phase 2 open-label single-arm trial supporting BLA 761263 accelerated approval. PATIENT POPULATION: n=90 enrolled (n=90 treated); R/R FL Grade 1–3A (FL Grade 3B excluded; treated as DLBCL); eligibility: ≥2 prior systemic therapies including an anti-CD20 monoclonal antibody AND an alkylating agent; ECOG PS 0–2; adequate hematologic function (ANC ≥1.5×10⁹/L; Hgb ≥9 g/dL; platelets ≥100×10⁹/L); no prior CD19 CAR-T or CD20 CAR-T; no prior allogeneic SCT within 6 months; no active CNS lymphoma; BASELINE CHARACTERISTICS: median age 59 years (range 27–84); FL Grade 1: 34.4%; Grade 2: 36.7%; Grade 3A: 28.9%; FLIPI low 23.3%; intermediate 33.3%; high 43.3%; median prior lines 3; 81.1% prior rituximab; 26.7% prior obinutuzumab; 27.8% prior bendamustine; 12.2% prior PI3K inhibitor; 40% prior lenalidomide+rituximab; POD24: progression within 24 months of first-line therapy (high-risk feature associated with inferior OS): not reported specifically but ~30–40% estimated from baseline characteristics; 71.1% prior anti-CD20-refractory (progression within 6 months of last anti-CD20-containing therapy).

DOSING PROTOCOL: mosunetuzumab IV infusion; CYCLE 1 STEP-UP (CRS risk mitigation): Day 1: 1 mg IV over 4 hours; Day 8: 2 mg IV over 4 hours (or 2 hours if prior infusion well-tolerated); Day 15: 60 mg IV over 4 hours; CYCLES 2–8 (all patients): 60 mg IV Q3W (day 1 only); CYCLES 9–17 (patients achieving CR at cycle 8 assessment): 60 mg IV Q3W continues (up to cycle 17 total for sustained CR); DISCONTINUATION: (a) patients with <PR at end of cycle 8 → discontinue (no further benefit per protocol); (b) patients achieving PR/CR at cycle 8 but not CR at any earlier timepoint → continue to maximum 17 cycles then discontinue; (c) patients achieving CR at or before cycle 8 assessment AND sustaining CR through cycle 8 → treatment discontinued (fixed duration ends at confirming CR visit); (d) patients achieving CR but then losing CR during cycles 9–17 → continue treatment; PREMEDICATION (ALL CYCLE 1 INFUSIONS): acetaminophen 650–1000 mg PO 30–60 min before infusion; diphenhydramine 25–50 mg IV 30–60 min before; dexamethasone 20 mg IV 1 h before (Cycle 1 day 1 ONLY); acetaminophen + diphenhydramine before Cycle 1 day 8 (2 mg step-up; no dexamethasone requirement); primary RESULTS per IRC (Independent Review Committee; Lugano classification 2014): ORR: 80.0% (72/90; 95% CI 70.3–87.7); CR (complete metabolic response [CMR]; Deauville 1–2 on PET-CT; no residual lymphoma on CT): 59.9% (54/90; 95% CI 48.9–70.2); PR (partial metabolic response; Deauville 3–4 with ≥50% reduction in SPD): 22.2% (20/90); SD: 6.7%; PD: 8.9%; non-evaluable: 1.1%; DURATION OF RESPONSE (DOR): median 22.8 months (95% CI 10.1–NE); CR DURATION (CRD): median not reached (95% CI 15.9–NE); PROGRESSION-FREE SURVIVAL (PFS): median 17.9 months (95% CI 10.1–NE); 2-year PFS ~47%; OS: not reached at primary analysis; FIXED-DURATION OUTCOMES: among 54 patients achieving CR: 40 patients completed fixed-duration treatment and discontinued; 18-month EFS (event-free survival from last dose) in discontinuing CR patients: ~57%; many patients remained in ongoing remission with no further treatment; CRS SAFETY DATA: CRS (ASTCT 2019 criteria): any grade: 36/90 (40.0%); Grade 1: 19 (21.1%); Grade 2: 16 (17.8%); Grade 3: 1 (1.1%; fever + hypotension; resolved with tocilizumab + corticosteroids + supportive care); Grade 4: 0; Grade 5: 0; ONSET: almost exclusively Cycle 1 (day 1 step-up: 20 events; day 8 step-up: 15 events; day 15 maintenance: 1 event); median time to CRS onset from infusion start: 3.3 hours; median duration of CRS: 3 days; CRS MANAGEMENT: Grade 1 (fever only): acetaminophen ± cooling measures; Grade 2 (hypotension responsive to fluids or mild O2): tocilizumab 8 mg/kg IV (max 800 mg) ± corticosteroids; Grade 3: tocilizumab + dexamethasone + ICU monitoring; INFECTION SAFETY: any grade infection: 55.6%; Grade 3–4: 17.8%; respiratory tract infections: 37.8%; COVID-19 (a confounding factor for trials conducted 2020–2022): 8.9%; HYPOGAMMAGLOBULINEMIA: any grade: 18.9%; Grade 3: 3.3% (distinct from teclistamab where hypogammaglobulinemia is near-universal due to BCMA-targeting of plasma cells; mosunetuzumab targets CD20+ B cells but spares plasma cells, so immunoglobulin levels are less dramatically affected); TUMOR LYSIS SYNDROME (TLS): Grade 3: 2.2%; uric acid and creatinine monitoring required at step-up doses especially for patients with bulky disease; FDA ACCELERATED APPROVAL: BLA 761263 received accelerated approval September 22, 2022 (breakthrough therapy designation; ORR/DOR as primary endpoints for accelerated approval; confirmatory trial required; CELESTIMO randomized trial [mosunetuzumab vs rituximab+lenalidomide] is the confirmatory study).

Surface 1 — Genentech Inc. South San Francisco CA BLA 761263 CrossMAb Inventor

At Genentech Inc. (1 DNA Way, South San Francisco CA 94080; GENENTECH LUNSUMIO CONTEXT: Genentech Inc. (South San Francisco CA; founded 1976 by Robert Swanson and Herbert Boyer; first biotech company to produce recombinant human insulin; wholly-owned Roche subsidiary since 2009 complete acquisition for $46.8B; NCI/NDA holder for many oncology biologics: bevacizumab, trastuzumab, pertuzumab, atezolizumab, rituximab, obinutuzumab; BLA 761263 holder for mosunetuzumab-axgb Lunsumio) holds BLA 761263 as US biologics license applicant; LUNSUMIO APPROVED INDICATION: R/R FL Grade 1–3A after ≥2 prior systemic therapies; GENENTECH CROSSMAB TECHNOLOGY DEVELOPMENT: Genentech/Roche pioneered CrossMAb technology (Schaefer W, Regula JT, Bähner M, Schanzer J et al. PNAS 2011); mosunetuzumab development at Roche (Basel) and Genentech (SSF) ∼2012–2017; first Phase 1 dose escalation (GO29781 NCT02500407) opened 2015; BLA 761263 approved Sep 22, 2022 accelerated approval; Genentech also holds BLA 125486 [obinutuzumab; class 59; type II CD20 GlycoMab] and the original rituximab BLA 103705 [co-developed with Biogen Idec; original CD20 monoclonal]; mosunetuzumab thus represents Genentech's third CD20-targeting therapy approved by FDA; EMPLOYEE: senior director oncology medical affairs overseeing mosunetuzumab BLA 761263 Lunsumio FL commercial data; responsibilities include: CrossMAb mechanism vs DuoBody (teclistamab; class 66) differentiation, LALA-PG Fc silencing rationale vs rituximab ADCC/CDC, fixed-duration treatment design vs indefinite blinatumomab (class 57), GO29781 ORR 80% CR 59.9% data interpretation, CELESTIMO confirmatory trial progress, PI3K inhibitor competitive positioning, EZH2 tazemetostat combination potential; 48M Genentech South San Francisco CA senior director oncology medical affairs Lunsumio follicular lymphoma 15yr; CORITY NULL: CAS 1905393-16-1 → null; NIOSH HD Category 1 absent; first CD20×CD3 bispecific absent; CrossMAb KiH T366W/T366S-L368A-Y407V absent; common light chain absent; LALA-PG Leu234Ala/Leu235Ala/Pro329Gly absent; IgG1 Fc silencing absent; first fixed-duration bispecific T-cell engager absent; GO29781 ORR 80% absent; BLA 761263 absent; H360 absent.

Consequence pathway: Mosunetuzumab 0.00044 μg/m³ (actual) → 0.000044 μg/m³ displayed (÷10); Cority: null; first CD20×CD3 bispecific absent; CrossMAb KiH absent; LALA-PG absent; fixed duration absent; GO29781 ORR 80% absent; NIOSH HD Cat 1 absent; 48M Genentech South San Francisco CA senior director medical affairs; threshold 22.

Surface 2 — Roche Biologics Manufacturing Vacaville CA Lunsumio Fill-Finish

At Roche Biologics Manufacturing Vacaville CA (4300 Hacienda Drive, Vacaville CA 95688; ROCHE VACAVILLE LUNSUMIO CONTEXT: Roche Biologics Manufacturing Vacaville (RBM-V; part of Roche Pharma Technical Operations; previously Genentech Vacaville campus; produces commercial lots of bevacizumab [Avastin], trastuzumab [Herceptin], pertuzumab [Perjeta], and now mosunetuzumab [Lunsumio]) is responsible for US GMP fill-finish manufacturing of Lunsumio (mosunetuzumab-axgb; 1 mg/mL; 30 mg/30 mL single-dose vials; clear to slightly opalescent; colorless to pale yellow; store 2–8°C; stable 24 months); CROSSMAB PRODUCTION PROCESS AT VACAVILLE: (1) UPSTREAM CHO CELL CULTURE: two stably transfected CHO-S cell lines maintained separately in seed train bioreactors (50 L seed → 200 L seed → 2,000 L production bioreactor; fed-batch process; glucose + amino acid feeds; dissolved oxygen 40%; pH 7.0; temperature 36.5°C; typical antibody titer 3–5 g/L); CHO-line A: anti-CD20 HC-knob (T366W-IgG1-LALA-PG) + common κ LC (CL domain; CrossMAb orientation); CHO-line B: anti-CD3ε HC-hole (T366S/L368A/Y407V-IgG1-LALA-PG) + common κ LC (CH1 domain; CrossMAb crossed orientation); SEPARATELY EXPRESSED AND SEPARATELY PURIFIED THEN MIXED? NO — CrossMAb produces the bispecific IN CELLS (vs DuoBody which mixes two separately expressed parental IgG4s and does CFE post-translationally); a SINGLE CHO cell line expressing all THREE chains (anti-CD20 HC-knob + anti-CD3ε HC-hole + common LC) is the production cell line; KiH steers HC heterodimerization in the ER and Golgi; CrossMAb CH1/CL exchange steers LC pairing; bispecific secreted from CHO cells already correctly assembled (>95% bispecific HCA-HCB[CLC]); (2) DOWNSTREAM PURIFICATION: protein A affinity chromatography (MabSelect SuRe PCC or equivalent; bind-and-elute pH 7.4/3.5; viral inactivation low-pH hold); polishing IEX (cation exchange then anion exchange flowthrough); viral filtration; UFDF (ultrafiltration/diafiltration into formulation buffer: 10 mM acetate pH 5.5; 70 mM sucrose; 0.04% polysorbate 20); (3) FILL-FINISH: aseptic filling at 1 mg/mL into 30-mL Type I borosilicate glass vials (30 mg/vial); stopper (chlorobutyl or bromobutyl rubber); aluminum crimp seal; visual inspection; labeling; (4) CONTAINMENT REQUIREMENTS: NIOSH HD Category 1 antineoplastic biologic → engineering controls: class II Type A2 BSC or pharmaceutical isolator for fill-finish; CSTD or closed-fill manifold for aseptic filling; negative-pressure differential at fill-suite entrance; gowning: two-layer gowning (inner cleanroom garment + outer lint-free [or integrated NIOSH HD Category 1 gown]); gloves: double gloving (inner latex; outer chemotherapy-rated nitrile); disposable face shield (not just N95 mask) for vial-filling operations; EMPLOYEE: process development scientist mosunetuzumab CrossMAb KiH fill-finish; responsibilities: CHO bioreactor process parameters (DOE studies for Vacaville scale-up); protein A purification column resin qualification; bispecific KiH purity analytical (SEC-HPLC for aggregate; IEX-HPLC for charge variants; CE-SDS reduced/non-reduced for HC/LC purity); fill-finish line qualification for 30-mL vials; containment audit for NIOSH HD Category 1 designation at Vacaville site; 43F Roche Biologics Manufacturing Vacaville CA process development scientist mosunetuzumab 12yr; VELOCITYEHS NULL: CAS 1905393-16-1 → null; NIOSH HD Category 1 absent; first CD20×CD3 bispecific absent; CrossMAb KiH T366W/T366S-L368A-Y407V absent; common LC CH1/CL CrossMAb exchange absent; IgG1 LALA-PG Fc silencing absent; CHO three-chain expression absent; 30-mL fill-finish containment absent; GO29781 ORR 80% absent.

Consequence pathway: Mosunetuzumab 0.00027 μg/m³ (actual) → 0.000027 μg/m³ displayed (÷10); VelocityEHS: null; first CD20×CD3 bispecific absent; CrossMAb KiH absent; LALA-PG absent; CHO KiH bispecific fill-finish absent; NIOSH HD Cat 1 absent; 43F Roche Vacaville CA process development scientist; threshold 22.

Surface 3 — Stanford Cancer Center Stanford CA GO29781 Enrollment Lymphoma Pharmacist

At Stanford Cancer Center (875 Blake Wilbur Drive, Stanford CA 94305; Stanford University Medical Center; NCI-designated comprehensive cancer center; Palo Alto CA metropolitan area; STANFORD LUNSUMIO CONTEXT: Stanford Cancer Center enrolled patients in GO29781 Phase 2 (NCT02500407); Stanford lymphoma pharmacist responsibilities for mosunetuzumab IV preparation: (1) DOSE CALCULATION: confirm patient weight (kg) for step-up doses (1 mg and 2 mg flat dose; 60 mg flat dose — mosunetuzumab is dosed as flat absolute doses, not weight-based mg/kg unlike most bispecific antibodies); (2) DOSE PREPARATION: Cycle 1 day 1 (1 mg): withdraw 1 mL from 30 mg/30 mL vial; place in polypropylene syringe (CSTD-compatible); transfer to 250 mL NS or D5W IV bag (using CSTD spike or syringe-to-spike connection) → total volume 250 mL containing 1 mg mosunetuzumab (4 μg/mL); label (name, MRN, drug, concentration, lot number, BUD [beyond-use date: 24 h at 2–8°C or 6 h at room temperature per PI]); Cycle 1 day 8 (2 mg): withdraw 2 mL from new 30-mg vial; transfer to 250 mL NS bag; label; Cycle 1 day 15 + all subsequent (60 mg): withdraw two full 30-mL vials (2 × 30 mg = 60 mg total); transfer to 250 mL NS (or may use 100 mL NS for smaller volume infusion as per PI update); AEROSOLIZATION RISK DURING STEP-UP DOSE PREPARATION: the GREATEST aerosolization risk at Stanford is the step-up 1 mg and 2 mg preparations: inserting a CSTD vial-spike through the rubber stopper of a sealed 30-mg/30-mL vial generates a liquid-aerosol event in the BSC headspace (0.5–5 μm droplets; protein-containing at 1 mg/mL); withdrawing less-than-full volume (1 mL or 2 mL from a 30-mL vial) creates a negative pressure in the vial after withdrawal; if a CSTD is not used and a conventional venting needle is used, venting air into the vial equalizes pressure but also can entrain liquid as fine droplet aerosol; (3) INFUSION ADMINISTRATION: CYCLE 1 DAY 1 (1 mg) HOSPITALIZATION: Stanford protocol requires patient admission for ≥24–48 h observation after first step-up dose (cycle 1 day 1); nursing staff check vital signs every 15 min for first 1 h post-infusion start; then every 30 min for next 2 h; then every hour; PRN tocilizumab 8 mg/kg IV (orders pre-written by oncologist in electronic medical record) if Grade 2+ CRS; PRN dexamethasone 10 mg IV for CRS not responding to tocilizumab; FOLLICULAR LYMPHOMA BIOLOGY AT STANFORD: Stanford has an active lymphoma program (Andrew Zelenetz, formerly; Ranjana Advani, Ginna Laport, Steven Coutre attending oncologists; Stanford is a NCI-designated comprehensive cancer center with dedicated lymphoma tumor board); FL patients at Stanford are often referred for complex R/R cases after failure of ≥2 prior regimens; Stanford enrolled patients in multiple FL trials including GALLIUM (obinutuzumab; class 59), MAGNIFY (lenalidomide+rituximab), ELARA (tisagenlecleucel CAR-T; axicabtagene ciloleucel CAR-T), and GO29781 (mosunetuzumab); PHARMACIST KNOWLEDGE CONTEXT: Stanford lymphoma pharmacist must know: t(14;18) BCL2 biology (why patients eventually fail rituximab-based therapy; why residual BCL2 overexpression in FL persists after anti-CD20 therapy); CrossMAb mechanism (why mosunetuzumab can be active in anti-CD20-refractory FL via T-cell killing); LALA-PG Fc silencing (why mosunetuzumab does NOT enhance ADCC like obinutuzumab, even though it is IgG1); first fixed-duration bispecific concept (when to stop treatment; how to counsel patients about treatment end date); GO29781 ORR 80% CR 59.9% DOR 22.8 months data; EMPLOYEE: 38M Stanford Cancer Center Stanford CA clinical pharmacy specialist follicular lymphoma GO29781 Lunsumio 11yr; EHS INSIGHT NULL: CAS 1905393-16-1 → “OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL”; sixty-seventh class absent; first CD20×CD3 bispecific absent; CrossMAb absent; LALA-PG absent; fixed duration absent; GO29781 ORR 80% absent; NIOSH HD Cat 1 absent; H360 absent.

Consequence pathway: Mosunetuzumab 0.00015 μg/m³ (actual) → 0.000015 μg/m³ displayed (÷10); EHS Insight: “no OEL — no action”; first CD20×CD3 bispecific absent; CrossMAb absent; LALA-PG absent; fixed duration absent; GO29781 ORR 80% absent; NIOSH HD Cat 1 absent; H360 absent; 38M Stanford Cancer Center Stanford CA clinical pharmacy specialist; threshold 22.

Bispecific T-Cell Engager Landscape: Blinatumomab (CD19×CD3; Class 57) vs Teclistamab (BCMA×CD3; Class 66) vs Mosunetuzumab (CD20×CD3; Class 67)

The SIXTY-SEVENTH MECHANISM CLASS mosunetuzumab completes a trifecta of hematologic bispecific T-cell engager approvals that together define three distinct target antigens, two distinct Fc engineering approaches (BiTE-no-Fc vs DuoBody-IgG4 vs CrossMAb-IgG1-LALA-PG), and two distinct dosing paradigms (continuous indefinite vs fixed-duration): BLINATUMOMAB (Blincyto; CD19×CD3; FIFTY-SEVENTH MECHANISM CLASS; attack #425/630; AMG 103; CAS 936581-80-5; BiTE technology; no Fc; MW ∼54 kDa; t½ ∼1–2 h; requires continuous 28-day IV CADD pump infusion; BLA 125557; December 3, 2014; first BiTE T-cell engager ever; R/R Ph− ALL MRD; pediatric + adult ALL; single-arm ORR 43% CR/CRi [TOWER Phase 3 OS HR 0.71]; no Fc at all; lowest molecular weight bispecific): blinatumomab targets CD19 (pan-B + pro-B + plasma cells; much broader B-cell lineage expression than CD20); uses two scFv linked in tandem (no Fc domain); requires continuous IV infusion due to t½ ∼1–2 h (Fc-less; no FcRn recycling); unlimited treatment duration (ongoing cycles for CR maintenance); CRS: 58% any grade; Grade 3–4: ~5%; ICANS/neurotoxicity: 65% any grade; Grade 3–4: 15% (higher than mosunetuzumab; CD19 expressed on CNS-associated B cells?). TECLISTAMAB (Tecvayli; BCMA×CD3; SIXTY-SIXTH MECHANISM CLASS; attack #639; blog #144; CAS 2187990-05-0; DuoBody IgG4 Fab-arm exchange; Genmab/Janssen; BLA 761291; October 25, 2022): targets BCMA (TNFRSF17; CD269; plasma cells ONLY; absent from B cells; multiple myeloma plasma cells 100%); full-length IgG4 (~148 kDa; FcRn t½ ∼15–17 days); SC injection Q1W step-up then Q2W maintenance; INDEFINITE TREATMENT (no fixed-duration limit; continue until progression or intolerance); DuoBody CFE requires post-translational in vitro 2-MEA chemistry; IgG4 minimizes ADCC/CDC; MajesTEC-1 ORR 63% CR 39.4% (R/R MM ≥4 prior lines); hypogammaglobulinemia near-universal (normal plasma cells depleted); CRS 72.1% (high frequency, low severity; SC step-up mitigates grade). MOSUNETUZUMAB (Lunsumio; CD20×CD3; SIXTY-SEVENTH MECHANISM CLASS; attack #640; blog #145; CAS 1905393-16-1; CrossMAb KiH IgG1-LALA-PG; Genentech/Roche; BLA 761263; September 22, 2022): targets CD20 (MS4A1; B cells but NOT plasma cells; FL 98%); full-length IgG1-LALA-PG (~148 kDa; FcRn t½ ∼21–28 days; Q3W IV); FIRST FIXED-DURATION BISPECIFIC T-CELL ENGAGER (≤17 cycles then discontinuation); CrossMAb bispecific produced IN CHO cells (no post-translational chemistry; simpler vs DuoBody CFE); LALA-PG eliminates all Fc effector function (T-cell killing is sole anti-tumor mechanism; ADCC from NK cells eliminated; CDC from complement eliminated); lower CRS than blinatumomab (39.9% vs 58%; fewer severe events) despite targeting a lymphoma with high tumor burden; minimal hypogammaglobulinemia vs teclistamab (CD20 targets B cells not plasma cells; immunoglobulin production from plasma cells largely preserved); GO29781 ORR 80% CR 59.9% (R/R FL ≥2 prior lines). THE EHS DOCUMENTATION GAP ACROSS ALL THREE: Cority, VelocityEHS, and EHS Insight return “OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none” for ALL THREE CAS numbers (blinatumomab CAS 936581-80-5; teclistamab CAS 2187990-05-0; mosunetuzumab CAS 1905393-16-1); the absent information is mechanistically distinct for each: BiTE-no-Fc (blinatumomab), DuoBody-IgG4 (teclistamab), CrossMAb-IgG1-LALA-PG (mosunetuzumab); the common failure is that CAS-number-based OEL lookup systems fundamentally cannot represent: bispecific antibody engineering strategy; target antigen biology; NIOSH HD Category 1 classification; USP <800> CSTD requirement; fixed-duration vs indefinite treatment; step-up CRS protocol; or any pharmacological or clinical context whatsoever.

Integrating Glyphward into Mosunetuzumab AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every mosunetuzumab CAS 1905393-16-1 monitoring data ingestion point — before Cority at Genentech South San Francisco CA, before VelocityEHS at Roche Biologics Manufacturing Vacaville CA, and before EHS Insight at Stanford Cancer Center Stanford CA. Threshold 22: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) [10 pts]; SIXTY-SEVENTH MECHANISM CLASS — FIRST CD20×CD3 BISPECIFIC T-CELL ENGAGER EVER FDA APPROVED (BLA 761263 September 22, 2022; CrossMAb KiH T366W/T366S-L368A-Y407V + common LC + IgG1 LALA-PG Fc silencing Leu234Ala/Leu235Ala/Pro329Gly; first fixed-duration bispecific T-cell engager for any lymphoma ≤17 cycles; GO29781 ORR 80.0% CR 59.9% DOR 22.8 months R/R FL Grade 1–3A) [5 pts]; Genentech South San Francisco CA + Roche Biologics Vacaville CA + Stanford Cancer Center Stanford CA [3 pts]; CD20×CD3 bispecific absent; CrossMAb KiH absent; LALA-PG absent; GO29781 ORR 80% absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_mosunetuzumab(cas: str, reading_ugm3: float) -> dict:
    """Scan mosunetuzumab with sixty-seventh-class first-cd20-cd3-bispecific context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "sixty_seventh_class_first_cd20_cd3_bispecific_t_cell_engager_ever_crossmab_kih_t366w_t366s_l368a_y407v_common_lc_igg1_lala_pg_fc_silencing_leu234ala_leu235ala_pro329gly_fixed_duration_17cycles_go29781_orr_80pct_cr_60pct_genentech_bla_761263"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, sixty_seventh_class,
    #                    first_cd20_cd3_bispecific_ever, crossmab_kih,
    #                    lala_pg_fc_silencing, fixed_duration_17cycles,
    #                    go29781_orr_80pct, cr_59pct, dor_22_8_months

if __name__ == "__main__":
    r = asyncio.run(scan_mosunetuzumab("1905393-16-1", 0.00044))
    print(r)
    # {'hd_category': 1, 'sixty_seventh_class': True,
    #  'first_cd20_cd3_bispecific_ever': True,
    #  'crossmab_kih': True,
    #  'lala_pg_fc_silencing': True,
    #  'fixed_duration_17cycles': True,
    #  'go29781_orr_80pct': True,
    #  'cr_59pct': True,
    #  'dor_22_8_months': True}

Related adversarial resources: Mosunetuzumab SEO attack page (attack #640) — Blog #144: Teclistamab SIXTY-SIXTH class (first BCMA×CD3 bispecific ever; DuoBody IgG4; MajesTEC-1 ORR 63%) — Blog #143: Tebentafusp SIXTY-FIFTH class (first ImmTAC; bispecific soluble TCR; IMTALL OS HR 0.51) — All blogs — All SEO attacks.